Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cencora, Inc. Common Stock (NY: COR )

237.25 -2.80 (-1.17%)
Streaming Delayed Price Updated: 12:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cencora, Inc. Common Stock

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
From Cencora
Via Business Wire
Cencora Completes Acquisition of Retina Consultants of America
From Cencora
Via Business Wire
Cencora Closes $1.8 Billion Senior Notes Offering
From Cencora
Via Business Wire
Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
From Cencora
Via Business Wire
Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
From Cencora
Via Business Wire
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
From Cencora
Via Business Wire
Cencora Expands Enterprise Leadership Team with Two Senior Appointments
From Cencora
Via Business Wire
Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy
Walgreens Boots Alliance (WBA) is down 60% from its 52-week high, but improving earnings, cost cuts, and a 9.27% dividend yield signal potential recovery. 
Via MarketBeat
Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
Cencora Elects Frank Clyburn to Its Board of Directors
From Cencora
Via Business Wire
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds
From Walgreens Boots Alliance
Via Business Wire
Cencora Reports Fiscal 2024 Third Quarter Results
From Cencora
Via Business Wire
Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
From Cencora
Via Business Wire
Cencora Reports Fiscal 2024 Second Quarter Results
From Cencora
Via Business Wire
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
Cencora Announces Leadership Succession Plan
From Cencora
Via Business Wire
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
From Walgreens Boots Alliance
Via Business Wire
Cencora Closes $500 Million Senior Notes Offering
From Cencora
Via Business Wire
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
From Cencora
Via Business Wire
Cencora Reports Fiscal 2024 First Quarter Results
From Cencora
Via Business Wire
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
From Cencora
Via Business Wire
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
From Cencora
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.